Bioasis & Prothena in the news...The November/December issue of
NeuroPerspective, a prestigious and exclusive (US $2700/yr) journal that publishes news and analysis about neurotherapeutics, has reported the Bioasis/Prothena deal on the cover's inside page (p.2), the News and Develoments, Partnering/M&A section. The journal's home page shows the first three pages of the September/October edition. Perhaps in November they'll show a similar shot of the November/December edition, including the reference to Bioasis and Prothena.
It's a brief report but it's right where we want it to be.
Many of you might remember what I predicted could happen once we started getting attention in the biotech, financial and popular media. This is the type of attention I discussed.
jdstox